Bristol-Myers Squibb's Pipeline in Focus: Key Clinical Data Readouts Could Catalyze Stock Rebound
Analysts at Leerink Partners have raised their price target for Bristol-Myers Squibb (BMY), highlighting a series of pivotal clinical trial results expected in 2025. The firm sees significant upside potential as the market currently undervalues the company's robust pipeline, despite near-term earnings adjustments.